Skip to main content
Triangle logo TriangleGet started

Niraparib (NCT06747845)

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy: a one-minute explainerNCT067478451 min

Niraparib trial for Pancreatic Adenocarcinoma Metastatic (NCT06747845). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic pancreatic adenocarcinoma controlled after four to six months of first-line FOLFIRINOX or NALIRIFOX. Known BRCA1/2, PALB2 or RAD51C/D pathogenic alterations and mismatch-repair-deficient or MSI-high cancers are excluded.

The idea: compare daily oral niraparib, which blocks DNA repair, plus four ipilimumab infusions, which release an immune brake, against FOLFIRI chemotherapy every two weeks. Researchers measure progression and safety. Before-treatment and on-treatment biopsies are required when medically feasible. Previous PARP or CTLA-4 inhibitors exclude entry.

This phase 2 study plans 68 patients. Penn sponsors two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.